An NO donor approach to neuroprotective and procognitive estrogen therapy overcomes loss of NO synthase function and potentially thrombotic risk.

Additionally, clinical trials showed a trend towards decreased risk for cognitive impairment [18] , [19] , with no effect on coronary events, although these effects must be balanced against raloxifene's known increased lifetime risk of thromboembolic events [20] .

also in 53,322 other papers

At 1 h, both DMA and NO-DMA significantly increased aPTT, while only NO-DMA significantly increased PT, though DMA showed a clear trend ( Fig. 6 ).

also in 19,460 other papers